| Assessment Status | Rapid Review Complete |
| HTA ID | 24045 |
| Drug | Ribociclib |
| Brand | Kisqali® |
| Indication | Ribociclib in combination with an aromatase inhibitor (AI) is indicated for the adjuvant treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 13/11/2024 |
| Rapid review completed | 19/12/2024 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that ribociclib not be considered for reimbursement at the submitted price*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
